Inclusion and exclusion criteria
All the RCTs reporting the application of TKLS for stable COPD were included in the study. There were no limitations on publication status. The inclusion criteria were the following: (1) articles published in English or Chinese language; (2) randomized or quasi-randomized clinical trials; (3) studies including patients diagnosed with stable COPD; and (4) studies including patients treated according to syndrome differentiation (TCM).
The exclusion criteria were (1) randomized crossover trials, case reports, case series, reviews, qualitative studies, or animal experiments and (2) stable COPD interventions being combined with external therapy of TCM.
Intervention type
RCTs that examined the effects of TKLS combined with the conventional Western medicine (CWM) and CWM were identified. Patients in the treatment group were given TKLS combined with CWM, whereas patients in the control group were treated with CWM. Patients were excluded when the RCTs included external therapy of TCM. We did not set limitations on dosages and course of treatment.
Outcome measures
The primary outcomes analyzed in this meta-analysis were clinical effectiveness, TCM Syndrome Score, [9] exercise capacity (6-min walk distance in meters [6 mWD]), [10] and respiratory-specific quality of life (St George's Respiratory Questionnaire [SGRQ] ). [11] The secondary outcomes analyzed for this meta-analysis were lung function (FEV1%), T-lymphocyte subsets (CD4, CD8, and CD4/CD8), and immunoglobulin (IgA, IgG, and IgM). Safety and adverse events were also included.
Literature search strategy
Two Chinese-language databases and two English-language databases were widely searched for all relevant results until December 2017. The Chinese-language databases were China National Knowledge Infrastructure and China Biology Medicine disc. The two English-language databases were PubMed and Cochrane Library.
The search strategy was the following: #1 Bushen; #2 Bu shen; #3 Yishen; #4 nourishing the kidney; #5 tonifying the kidney; #6 Yi shen; #7 tonifying shen; #8 tonifying kidney; #9 nourishing kidney; #10 nourishing shen; #11 reinforcing the kidney; #12 reinforcing kidney; #13 reinforcing shen; #14 Invigorating the kidney; #15 Invigorating kidney; #16 Invigorating shen; #17 kidney-reinforcing; #18 kidney reinforcing; #19 Shen reinforcing; #20 Shen-reinforcing; #21 kidney-Invigorating; #22 kidney Invigorating; #23 Shen-Invigorating; #24 kidney-tonifying; #25 Shen-tonifying; #26 kidney tonifying; #27 Shen tonifying; #28 Shen Invigorating; #29 Invigorating Shen; #30 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 reinforcing kidney or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29; #31 COPD; #32 chronic obstructive pulmonary disease; #33 #31 or #32; #34 #30 and #33.
Data extraction and management
Data were extracted by two reviewers independently. After checking, any disagreements were resolved by consulting a third reviewer. All the data were recorded using a data collection form. The form contents were as follows: (1) title, authors, source, and time of publication; (2) basic characteristics (sample, gender, age, diagnostic criteria, course of disease, intervention, course of treatment, main outcomes, and specific details); and (3) methods (study design, total study duration, sequence generation, allocation sequence concealment, blinding, and other concerns about bias). The collected outcome data were inputted into Review Manager 5.3 software (RevMan5.3, Cochrane Community, London, United Kingdom, 2014).
Assessment of risk of bias
Criteria for judging the risk of bias were taken from the "risk of bias" assessment tool in the Cochrane Handbook for Systematic Reviews of Interventions 5.1.0. [12] This judgment was evaluated by two reviewers independently, and the disagreements were resolved by consulting a third reviewer.
Data synthesis
RevMan 5.3 was used for statistical analysis. The extracted data were divided into dichotomous and continuous variables. Data were summarized using odds ratio with 95% confidence intervals (CI) for dichotomous outcomes; mean difference (MD) with 95% CI was presented for continuous outcomes. Cochrane's P values and I 2 tests were determined to examine the level of heterogeneity between trials. A random-effects model was used to evaluate the effects of TKLS on stable COPD if I 2 > 50% or P < 0.1. Otherwise, a fixed-effects model was utilized. P < 0.01 was considered statistically significant. Data were subjected to meta-analysis by using Review Manager 5.3 software.
results

Results of the search
A total of 560 potential records (507 records from Chinese databases and 53 records from English databases) were obtained. Among these, 418 records were left for further screening after removing the duplicates. A total of 171 studies were read and analyzed in detail, and 14 studies were finally included for the systematic review. This screening process is summarized in a flow diagram [ Figure 1 ].
Study characteristics
Among 14 studies, 1339 patients with COPD were included. The control group received CWM, whereas the experimental group received TKLS combined with the CWM. The study characteristics are shown in Table 1 .
Composition of the herbal formulas for chronic obstructive pulmonary disease in this review
Patients in the treatment group were treated with TKLS. The details of herbal medicines in the included studies are presented in Table 2 .
Risk-of-bias assessment
Five of the included articles described the specific method of randomization (four random number table and one randomized block design). None of them described the allocation concealment method. One of them was double-blind method research and one of them was single-blind method research [Figures 2, 3 and Table 3 ].
Meta-analysis
The meta-analysis was done according to random-effects statistical model. In addition, all the studies included treatment group patients (treated with TKLS combined with CWM) and control patients (treated with CWM).
The clinical effectiveness of TKLS was evaluated in 12
studies which included 587 treatment group patients and 584 controls. Our analysis revealed that TKLS combined with CWM can increase clinical effectiveness (relative risk = 1.25, 95% CI: 1.18-1.33, P < 0.00001).
A fixed-effects model was used [ Figure 4 ] 2. TCM Syndrome Score was evaluated in six studies, including 224 treatment group patients and 222 controls. Our analysis revealed that TKLS combined with CWM can decrease TCM Syndrome Score (MD −5.72, 95% CI: −8.31 to −3.14, P < 0.0001) [ Figure 5 ] Two studies evaluated the cough, sputum, and wheezing scores of TLSK in 69 treatment group patients and 70 controls. Our analysis revealed that TLSK combined with CWM can decrease cough score (MD −1.04, 95% CI: −1.62 to −0.46, P = 0.0004), sputum score (MD −1.09, 95% CI: −1.91 to −0.26, P = 0.010), and wheezing score (MD −0.56, 95% CI: −1.07 to −0.05, P = 0.03). A random-effects model was used [ Figure 6 . T-lymphocyte subsets (CD4, CD8, and CD4/CD8): CD4 was evaluated in five studies (244 treatment group patients and 240 controls), CD8 in four studies (214 treatment group patients and 210 controls), and CD4/CD8 in four studies (214 treatment group patients and 210 controls). Briefly, our data revealed that TLKS combined with CWM can increase CD4 (MD 9.84, 95% CI: 6.73-12.94, P < 0.00001) [ Figure 10 ], can decrease CD8 (MD −1.84, 95% CI: −3.62 to −0.06, P = 0.04 [ Figure 11 ], and can increase CD4/CD8 (MD 0.26, 95% CI: 0.20-0.32 P < 0.0001) [ Figure 12 ]. A fixed-effects model was used for analyzing CD4/CD8, whereas a random-effects model was used for evaluating CD4 and CD8 7. Immunoglobulin (IgA, IgG, and IgM) was evaluated in two studies, including 129 treatment group patients and 126 controls. Our analysis revealed that TLSK combined with CWM can increase IgM (MD 0.15, 95% CI: 0.10-0.20 P < 0.00001) [ Figure 13 ], but it has no effect in increasing IgA (MD 0.27, 95% CI: −0.10-0.64 P = 0.15) [ Figure 14 ] and IgG (MD 2.43, 95% CI: −0.70-5.57 P = 0.13) [ Figure 15 ]. A random-effects model was used for analyzing IgA and IgG, whereas a fixed-effects model was applied for IgM 8. Table 4 summarizes the frequency of acute exacerbation which was not included in the meta-analysis but reported in RCTs.
Safety and adverse events
Among 14 included RCTs, five RCTs (including 540 participants) mentioned safety evaluation [ Table 5 ], whereas two RCTs (including 120 participants) reported adverse events associated with TCM [ Table 6 ].
dIscussIon
Chronic obstructive pulmonary disease in traditional Chinese medicine
Tonifying kidney, lung, and spleen for chronic obstructive pulmonary disease According to TCM, COPD is mainly caused by the deficiency of lung, spleen, and kidney, which is the internal cause of acute exacerbation of COPD. [27] Being the source of growth and [14] Unclear Unclear Unclear Unclear Unclear Low risk Fan et al., 2012 [15] Unclear Unclear Unclear Unclear Unclear Unclear Yang, 2013 [16] Randomized block design [19] Unclear Unclear Unclear Unclear Unclear Unclear Gong, 2017 [20] Random number table  Unclear  Unclear  Unclear  Unclear Unclear Mei, 2016 [21] Unclear Unclear Unclear Unclear Unclear Unclear Liu, 2015 [22] Random number Liang, 2009 [17] TKLS combined with CWM 9 13 6 2 CWM 3 10 12 5 Hao et al., 2013 [26] TKLS combined with CWM 6 16 6 2 CWM 3 10 12 5 Fan et al., 2012 [15] TKLS combined with CWM 1.6±1.4/year CWM 3.8±1.8/year TKLS: Tonifying kidney, lung, and spleen, CWM: Conventional Western medicine , the Pi (spleen) provides the material basis for the acquired constitution, whereas the shen (kidney) as the origin of congenital constitution stores vital essence and energy. The mutual generation between the lung and kidney, i.e., Pi (spleen) and Shen (kidney) deficiency, is the basis of the incidence of COPD. Fei (lung) and Shen deficiency are the main features of stable COPD, whereas the Shen deficiency is the root cause. For stable COPD, TKLS is one of the most important treatments aiming at its pathogenesis. TKLS including herbs that can tonifying kidney, lung and spleen, Not the same as chemical drugs, one Chinese herb may have many multiple therapeutic effects, such as Chinese yam (Shan yao) can tonifying kidney, lung and spleen. whether TKLS is beneficial for stable COPD and which aspect, was not clear.
Summary of evidence
In the present systematic review, a total of 1339 patients with stable COPD were selected and analyzed from 14 RCTs. It was found that, compared with CWM, TKLS combined with CWM significantly improved the clinical effectiveness; 
Liver function (ALT and/or AST)
Renal function
Routine urine test
Stool routine examination Electrocardiogram
Routine blood tests Song, 2009 , ALT [14] 30/30 √ √ √ √ √ √ Fan et al., 2012, (ALT, AST) [15] 90/90 √ √ √ √ √ Yang, 2013, (ALT) [16] 71/71 √ √ √ √ √ Liang et al., 2013, (N/A) [18] 39/40 √ √ √ √ √ √ Liang et al., 2014 (N/A) [25] 39/40 √ √ √ √ √ √ T: Treatment group (TCM combined with western medicine), C: Control group (western medicine only) decreased TCM Syndrome Score and cough, sputum, and wheezing scores; decreased SGRQ; increased 6 mWD and FEV1%; increased CD4, CD8, and CD4/CD8; and increased IgA and IgM.
We did not find strong evidence to prove that TKLS was associated with any serious adverse events. However, five RCTs (including 540 participants) mentioned safety evaluation, whereas two RCTs (including 120 participants) reported adverse events associated with TCM. From this study, it was not possible to draw a firm conclusion about the safety of TKLS for stable COPD, but we found that adverse events such as stomach upset and stool frequency increased, which self-improved after stopping the consumption of Liang, 2009 [17] 30/30 Three participants reported stomach upset Ke, 2014 [24] 30/30 Participants reported increased stool frequency, with self-improvement T: Treatment group (TCM combined with western medicine), C: Control group (western medicine only) herbs. In this review, TKLS combined with CWM improved the clinical effectiveness (MD 6.49%); decreased TCM Syndrome Score and cough, sputum, and wheezing scores; decreased SGRQ; increased 6 mWD (for FEV1%, MD was 6.49%); increased CD4, CD8, and CD4/CD8; and increased IgM; this result might indicate the potential of TKLS in improving the clinical effectiveness, symptoms, respiratory-specific quality of life, exercise capacity, and lung function. TKLS was found beneficial in treating low immune function of stable COPD.
Overall, this analysis revealed the clinical effectiveness and safety of the use of TKLS combined with CWM for stable COPD. According to the above analysis, the clinical effectiveness of TKLS was encouraging. We can give stable COPD TKLS according to TCM syndrome differentiation, and TKLS were beneficial for stable COPD.
Limitations
The methodologic quality of this review was poor. Although all the studies were randomized, no trials involved sequence generation. No trials reported allocation concealment. If patients and implementers were aware of the interventions, this meta-analysis would directly result in performance and detection biases. Five trials reported adverse events, and these adverse events were described briefly. Therefore, a definite conclusion about the safety of TKLS could not be obtained.
conclusIons
For stable COPD, TKLS combined with CWM is superior to CWM alone with regard to clinical effectiveness, symptoms, and quality of life. The above conclusion needs to be validated by further well-designed, multicentric, large-scale, double-blinded RCTs. 
